RT Journal Article
SR Electronic
T1 Diagnosis of SARS-CoV-2 infection with LamPORE, a high-throughput platform combining loop-mediated isothermal amplification and nanopore sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.18.20195370
DO 10.1101/2020.09.18.20195370
A1 Leon Peto
A1 Gillian Rodger
A1 Daniel P Carter
A1 Karen L Osman
A1 Mehmet Yavuz
A1 Katie Johnson
A1 Mohammad Raza
A1 Matthew D Parker
A1 Matthew D Wyles
A1 Monique Andersson
A1 Anita Justice
A1 Alison Vaughan
A1 Sarah Hoosdally
A1 Nicole Stoesser
A1 Philippa C Matthews
A1 David W Eyre
A1 Timothy EA Peto
A1 Miles W Carroll
A1 Thushan I de Silva
A1 Derrick W Crook
A1 Cariad M Evans
A1 Steven T Pullan
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.18.20195370.abstract
AB LamPORE is a novel diagnostic platform for the detection of SARS-CoV-2 RNA that combines loop-mediated isothermal amplification with nanopore sequencing, which could potentially be used to analyse thousands of samples per day on a single instrument. We evaluated the performance of LamPORE against RT-PCR using RNA extracted from spiked respiratory samples and from stored nose and throat swabs collected at two UK hospitals. The limit of detection of LamPORE was 7-10 genome copies/µl of extracted RNA. This is above the limit achievable by RT-PCR but was not associated with a significant reduction of sensitivity in clinical samples. Positive clinical specimens came mostly from patients with acute symptomatic infection, and among these LamPORE had a diagnostic sensitivity of 99.1% (226/228 [95% CI 96.9–99.9%]). Among negative clinical specimens, including 153 with other respiratory pathogens detected, LamPORE had a diagnostic specificity of 99.6% (278/279 [98.0–100.0%]). Overall, 1.4% (7/514 [0.5–2.9]) of samples produced an indeterminate result on first testing, and repeat LamPORE testing on the same RNA extract had a reproducibility of 96.8% (478/494 [94.8–98.1]). This indicates that LamPORE has a similar performance to RT-PCR for the diagnosis of SARS-CoV-2 infection in symptomatic patients, and offers a promising approach to high-throughput testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in partnership with Public Health England (PHE), and the NIHR Oxford Biomedical Research Centre. LP is an NIHR clinical lecturer. DWE is a Robertson Foundation Fellow and Oxford NIHR Senior Research Fellow. PCM is funded by the Wellcome Trust (110110/Z/15/Z). TIdS is a supported by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The process for collection of the donated saliva was approved by the PHE Research Ethics and Governance Group. The protocol for the use of stored clinical samples at OUH and STH was reviewed by the Joint Research Office of OUH and the University of Oxford (our Institutional Review Board), and it was determined that the activity constituted service evaluation and service development. As such, it required neither sponsorship nor research ethics review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrimary data will be available in the supplementary material